Fleita is a Russian randomized, open-label, multicenter, comparative program for the evaluation of the efficacy and safety of the fixed combination drug Tarka (ABBOTT Laboratories, USA) versus optional sustained-release antihypertensive drugs in the treatment of patients with arterial hypertension and cognitive disorders (stepwise strategy)

Abstract

Lesion of the brain as a target organ in arterial hypertension (AH) is manifested not only by strokes, but also impaired cognitive functions. A number of foreign studies have revealed an independent association of death with cognitive impairment in elderly patients. However, the impact of AH on higher mental functions, including that in geriatric patients, has been little studied so far. The effect of antihypertensive drugs, including their fixed-dose combinations that are to be preferred in the pharmacotherapy of AH due to their high efficacy and safety, on cognitive functions also remains to be investigated. In this connection, the Russian FLEITA randomized, open-label, multicenter, comparative program for the evaluation of the efficacy and safety of the fixed-dose combination drug Tarka (ABBOTT Laboratories, USA) versus optional sustained-release antihypertensive drugs in the treatment of patients with arterial hypertension and cognitive disorders (stepwise strategy), its national coordinator being Professor I.E. Chazova, is being implemented under the aegis of the Russian Medical AH Society. The objective of the clinical FLEITA program is to study the clinical efficacy, tolerance, and safety of Tarka used in patients with AH and cognitive disorders. The paper also gives the task of the study, inclusion/exclusion criteria, and the design of the program.